---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-003722"
form_type: "8-K"
ticker: "PAYS"
cik: "0001496443"
company_name: "Paysign, Inc."
filed_at: "2026-05-12T20:05:48+00:00"
generated_at: "2026-05-12T21:31:58.569748+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Paysign Q1 2026 revenue $28.04M (+50.8% YoY); pharma up 81.9%, net income $5.44M

## Summary
- Revenue $28.04M, up 50.8% YoY; pharma $15.68M (+81.9%), plasma $11.75M (+24.9%).
- Net income $5.44M ($0.09 diluted EPS) vs $2.59M ($0.05); adj. EBITDA $10.59M, up 113.4%.
- Operating margin 23.8% vs 13.4% YoY; gross margin 65.0% from 62.9% on pharma mix shift.
- Active patient affordability programs 135 (net +45 in 12 months); plasma centers 573 (net +89).
- Q2 2026 guidance: revenue $26.2M-$26.7M; full-year revenue $106.5M-$110.5M, net income $13M-$16M.

## SEC filing metadata
- accession: 0001683168-26-003722
- form_type: 8-K
- ticker: PAYS
- cik: 0001496443
- company_name: Paysign, Inc.
- filed_at: 2026-05-12T20:05:48+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1496443/000168316826003722/0001683168-26-003722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1496443/000168316826003722/paysign_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-003722
- JSON: https://secwatch.observer/filing/0001683168-26-003722.json
- Plain text: https://secwatch.observer/filing/0001683168-26-003722.txt

## Key facts
- Earnings Releases
  Paysign, Inc. reported first quarter 2026 results: revenue $28.04 million, net income $5.44 million, or $0.09 per diluted share, EPS $0.09 per diluted share.
  - Period: first quarter 2026
  - Revenue: $28.04 million
  - Net income: $5.44 million, or $0.09 per diluted share
  - EPS: $0.09 per diluted share
  - Result: reported results
  source text: for the life sciences industries, today announced financial results for the first quarter 2026. First Quarter 2026 Financial Highlights · First quarter 2026 revenues of $28.04 million, up 50.8% from f irst quarter 2025 · First quarter 2026 pharma revenue increased to $15.68 million, an increase of 81.9% versus f irst quarter 2025; added 45 net patient
  evidence_url: https://www.sec.gov/Archives/edgar/data/1496443/000168316826003722/0001683168-26-003722-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.